Litcius/Paper detail

The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma

Jens Bedke, Laurence Albigès, Umberto Capitanio, Rachel Giles, Milan Hora, Börje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu‐Ghanem, Saeed Dabestani, Sergio Fernandéz‐Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex

2022European Urology52 citationsDOI

Topics & Concepts

MedicinePembrolizumabNivolumabAtezolizumabKidney cancerRenal cell carcinomaIpilimumabInternal medicineOncologyAdjuvantAdjuvant therapyImmunotherapyCancerRenal cell carcinoma treatmentBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma | Litcius